The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma.
CTCL
Sézary syndrome
mycosis fungoides
quality of life
treatment strategies
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
18
06
2020
accepted:
31
08
2020
pubmed:
24
10
2020
medline:
16
6
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Cutaneous T-cell lymphomas (CTCLs) have a chronic, relapsing course, and the most common subtypes are mycosis fungoides and Sézary syndrome. The disease causes visible skin alterations and can also cause alopecia, pruritus and pain, all of which can impact patients' health-related quality of life (HRQoL). The goal of treatment is to reduce symptoms and prevent disease progression. However, treatment recommendations are often based on low levels of evidence due to the lack of well-designed randomised clinical trials and treatment guidelines, and approved drugs vary considerably across different countries and regions. Currently, available treatments rarely lead to durable remissions and eventually become less effective, meaning patients often require multiple therapy changes. Skin-directed therapies (SDTs) are first-line treatments for early-stage CTCL, whereas systemic therapies may be needed for early-stage disease that does not respond to SDT or for advanced-stage disease. However, patients can experience significant side-effects with these treatments or may be unable to tolerate them. Hence, there is an unmet need for effective therapies with good safety profiles for the treatment of early- and late-stage CTCL. Here, we review current treatment guidelines, investigational and approved treatments, the impact of CTCL on patients' HRQoL, and the treatment of pruritus.
Identifiants
pubmed: 33095448
doi: 10.1111/bjh.17117
pmc: PMC7894136
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-696Subventions
Organisme : Kyowa Kirin
Informations de copyright
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Clin Cancer Res. 2012 Sep 15;18(18):5051-60
pubmed: 22850569
Eur J Cancer. 2017 May;77:57-74
pubmed: 28365528
Cancer. 2003 Sep 1;98(5):993-1001
pubmed: 12942567
Cancer Lett. 2009 Aug 8;280(2):233-41
pubmed: 19344997
Blood. 2004 Sep 1;104(5):1465-73
pubmed: 15142883
J Clin Oncol. 2010 Apr 10;28(11):1870-7
pubmed: 20212249
Br J Dermatol. 2018 Apr;178(4):e273-e274
pubmed: 29150837
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Cancer Res. 2014 Nov 1;74(21):6060-70
pubmed: 25361998
Cancer Sci. 2006 Nov;97(11):1139-46
pubmed: 16952304
BMC Cancer. 2017 Mar 16;17(1):200
pubmed: 28302100
J Eur Acad Dermatol Venereol. 2020 May;34(5):995-1003
pubmed: 31630443
J Pharmacol Exp Ther. 1998 Sep;286(3):1140-5
pubmed: 9732370
J Allergy Clin Immunol. 2003 May;111(5):1153-68
pubmed: 12743593
Onco Targets Ther. 2019 Feb 07;12:1085-1094
pubmed: 30799938
Acta Derm Venereol. 2010;90(1):12-7
pubmed: 20107719
Am J Hematol. 2019 Sep;94(9):1027-1041
pubmed: 31313347
Blood. 2011 Oct 13;118(15):4024-35
pubmed: 21841159
Br J Dermatol. 2020 Mar;182(3):770-779
pubmed: 31049926
Arch Dermatol. 2008 Jun;144(6):727-33
pubmed: 18559761
Exp Dermatol. 2015 Jan;24(1):75-8
pubmed: 25381841
J Med Econ. 2020 Oct;23(10):1142-1150
pubmed: 32644862
Blood. 2015 Sep 17;126(12):1452-61
pubmed: 26228486
Blood. 2003 Jun 1;101(11):4267-72
pubmed: 12543862
Int J Dermatol. 2012 Aug;51(8):930-4
pubmed: 22788808
Eur J Cancer. 2013 Jan;49(2):386-94
pubmed: 22981498
Transpl Int. 2006 Nov;19(11):927-36
pubmed: 17018129
Leuk Lymphoma. 2019 Mar;60(3):675-684
pubmed: 30160566
Bone Marrow Transplant. 2014 Nov;49(11):1360-5
pubmed: 25068422
Cancer Sci. 2018 Mar;109(3):794-802
pubmed: 29363235
Br J Dermatol. 2009 Apr;160(4):815-22
pubmed: 19120325
Br J Dermatol. 2019 Mar;180(3):496-526
pubmed: 30561020
J Am Acad Dermatol. 2009 Jan;60(1):39-50
pubmed: 18842323
J Invest Dermatol. 2000 Jan;114(1):117-21
pubmed: 10620126
J Clin Oncol. 2012 Nov 20;30(33):4091-7
pubmed: 23045580
Lancet Oncol. 2019 Aug;20(8):1160-1170
pubmed: 31253572
J Clin Oncol. 2001 Jan 15;19(2):376-88
pubmed: 11208829
Chin Clin Oncol. 2019 Feb;8(1):12
pubmed: 30525754
Haematologica. 2007 Jun;92(6):784-94
pubmed: 17550851
J Am Acad Dermatol. 2010 Dec;63(6):984-90
pubmed: 20889234
J Med Internet Res. 2019 Jan 07;21(1):e11302
pubmed: 30617041
J Clin Oncol. 2015 Nov 10;33(32):3766-73
pubmed: 26438120
Acta Derm Venereol. 2019 Jun 1;99(7):640-646
pubmed: 30868169
J Immunol. 2015 Mar 15;194(6):2942-53
pubmed: 25681335
J Pain Symptom Manage. 2013 Jan;45(1):114-9
pubmed: 22917715
Semin Immunopathol. 2017 Apr;39(3):269-282
pubmed: 27717961
Dermatol Clin. 2015 Oct;33(4):807-18
pubmed: 26433851
J Immunol Methods. 2017 Sep;448:51-58
pubmed: 28551309
Br J Dermatol. 2018 Oct;179(4):882-888
pubmed: 29451670
Cancer Manag Res. 2010 Feb 05;2:53-9
pubmed: 21188096
Br J Dermatol. 2020 Mar;182(3):799-800
pubmed: 31529492
Front Oncol. 2019 Apr 11;9:260
pubmed: 31032224
J Clin Oncol. 2020 Jan 1;38(1):20-28
pubmed: 31532724
Int J Mol Sci. 2017 Jun 29;18(7):
pubmed: 28661430
J Am Acad Dermatol. 2001 May;44(5):755-61
pubmed: 11312420
Ann Oncol. 2017 Oct 1;28(10):2517-2525
pubmed: 28961843
Chin Clin Oncol. 2019 Feb;8(1):11
pubmed: 30691274
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Clin Oncol. 2014 Oct 10;32(29):3347-8
pubmed: 25154828
Arch Dermatol. 2007 Jul;143(7):854-9
pubmed: 17638728
Invest New Drugs. 2019 Feb;37(1):109-117
pubmed: 29995287
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2014 Feb 20;123(8):1159-66
pubmed: 24335103
J Clin Oncol. 2010 Oct 10;28(29):4485-91
pubmed: 20697094
Blood. 2018 Jul 19;132(3):245-253
pubmed: 29699989
Blood. 2007 Jan 1;109(1):31-9
pubmed: 16960145
Arch Dermatol. 2007 Mar;143(3):423-4
pubmed: 17372114
Arch Dermatol. 2005 Mar;141(3):325-30
pubmed: 15781673
Chin Clin Oncol. 2019 Feb;8(1):10
pubmed: 30818958
An Bras Dermatol. 2018 Sep-Oct;93(5):680-685
pubmed: 30156617
Clin Lab Med. 2017 Sep;37(3):527-546
pubmed: 28802499
Eur J Cancer. 2013 Sep;49(13):2859-68
pubmed: 23735705
Arch Dermatol. 2003 Jul;139(7):857-66
pubmed: 12873880
Hautarzt. 2004 Dec;55(12):1130-6
pubmed: 15517116
Acta Derm Venereol. 2018 Feb 7;98(2):240-245
pubmed: 29048099
Br J Dermatol. 2014 Jun;170(6):1226-36
pubmed: 24641480
Chin Clin Oncol. 2019 Feb;8(1):2
pubmed: 30525758
Clin Cancer Res. 2010 Apr 1;16(7):2106-14
pubmed: 20233883
J Clin Oncol. 2007 Jul 20;25(21):3109-15
pubmed: 17577020
Invest New Drugs. 2017 Apr;35(2):217-226
pubmed: 28138828
Int J Cancer. 2010 Nov 1;127(9):2199-208
pubmed: 20127862
Eur J Cancer. 2006 May;42(8):1014-30
pubmed: 16574401
J Am Acad Dermatol. 2012 Oct;67(4):760-8
pubmed: 22285672
Haematologica. 2007 May;92(5):686-9
pubmed: 17488695
J Clin Oncol. 2007 Sep 20;25(27):4293-7
pubmed: 17709797
Leuk Lymphoma. 2013 Jan;54(1):69-75
pubmed: 22738414
Cancer. 2006 Nov 15;107(10):2504-11
pubmed: 17048251
Cancer Res. 2009 Mar 15;69(6):2365-74
pubmed: 19258503
J Am Acad Dermatol. 2006 Sep;55(3):543-4
pubmed: 16908377
Blood. 2007 Jul 15;110(2):479-84
pubmed: 17339420
Acta Derm Venereol. 2016 Nov 2;96(7):894-898
pubmed: 27001482
JAMA Dermatol. 2019 May 1;155(5):538-547
pubmed: 30892603
Cancer. 1981 Jun 1;47(11):2671-7
pubmed: 7260860
Cancer Cell. 2007 Aug;12(2):115-30
pubmed: 17692804
Br J Dermatol. 2020 Mar;182(3):807-809
pubmed: 31536644
Oncogene. 2006 Oct 30;25(51):6817-30
pubmed: 17072330
Blood. 2015 Jan 1;125(1):71-81
pubmed: 25336628
Blood. 2016 Aug 11;128(6):805-15
pubmed: 27268084
Invest New Drugs. 2018 Dec;36(6):1072-1084
pubmed: 30198057
J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2
pubmed: 24438970
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40
pubmed: 29878045